Open-label single-arm phase II study of Alimta [pemetrexed] in combination with oxaliplatin as first-line therapy in advanced gastric carcinoma

Trial Profile

Open-label single-arm phase II study of Alimta [pemetrexed] in combination with oxaliplatin as first-line therapy in advanced gastric carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Oxaliplatin; Pemetrexed
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Aug 2006 Status change
    • 28 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top